Abstract
Colchicine is a tricyclic alkaloid extracted from the herbaceous plant Colchicum autumnale. Known since antiquity for its therapeutic efficacy in the treatment of gout, colchicine was reintroduced in 19th century pharmacopeia, thanks to the work of the French chemists and pharmacists Pierre-Joseph Pelletier (1788-1842) and Joseph Bienaimé Caventou (1795-1877) who in 1819, isolated a peculiar substance in the roots of Colchicum autumnale. In 1833, the substance was further analyzed by the German pharmacist and chemist Philipp Lorenz Geiger (1785-1836), who coined the name colchicine. In 1884, the French pharmacist Alfred Houde (1854-1919) produced for the first time pure crystallized colchicine in granules of 1milligram which is still sold under this trade name in several countries. In the last two centuries, colchicine's indications were furthermore expanded. From anti-gout drug during antiquity and a diuretic in 19th century, colchicine is currently administered in several affections such as Adamantiades-Behcet's disease, familial Mediterranean fever, pericarditis and atrial fibrillation.
Keywords: Colchicum, pierre-joseph pelletier, joseph bienaimé caventou, history of pharmacology, gout, atrial fibrillation.
Current Pharmaceutical Design
Title:Isolating Colchicine in 19th Century: An Old Drug Revisited
Volume: 24 Issue: 6
Author(s): Marianna Karamanou*, Gregory Tsoucalas, Konstantinos Pantos and George Androutsos
Affiliation:
- University Institute of History of Medicine and Public Health, Lausanne,Switzerland
Keywords: Colchicum, pierre-joseph pelletier, joseph bienaimé caventou, history of pharmacology, gout, atrial fibrillation.
Abstract: Colchicine is a tricyclic alkaloid extracted from the herbaceous plant Colchicum autumnale. Known since antiquity for its therapeutic efficacy in the treatment of gout, colchicine was reintroduced in 19th century pharmacopeia, thanks to the work of the French chemists and pharmacists Pierre-Joseph Pelletier (1788-1842) and Joseph Bienaimé Caventou (1795-1877) who in 1819, isolated a peculiar substance in the roots of Colchicum autumnale. In 1833, the substance was further analyzed by the German pharmacist and chemist Philipp Lorenz Geiger (1785-1836), who coined the name colchicine. In 1884, the French pharmacist Alfred Houde (1854-1919) produced for the first time pure crystallized colchicine in granules of 1milligram which is still sold under this trade name in several countries. In the last two centuries, colchicine's indications were furthermore expanded. From anti-gout drug during antiquity and a diuretic in 19th century, colchicine is currently administered in several affections such as Adamantiades-Behcet's disease, familial Mediterranean fever, pericarditis and atrial fibrillation.
Export Options
About this article
Cite this article as:
Karamanou Marianna*, Tsoucalas Gregory, Pantos Konstantinos and Androutsos George, Isolating Colchicine in 19th Century: An Old Drug Revisited, Current Pharmaceutical Design 2018; 24(6) . https://dx.doi.org/10.2174/1381612824666180115105850
DOI https://dx.doi.org/10.2174/1381612824666180115105850 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Pharmacological Properties of Physical Exercise in The Elderly
Current Pharmaceutical Design HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview
Current Drug Metabolism Cardiovascular Manifestations of COVID-19
Current Cardiology Reviews Cytotoxic T Lymphocyte Antigen 4 Gene +49 A/G (rs231775) Polymorphism and Susceptibility to Systemic Lupus Erythematosus
Current Rheumatology Reviews Clinical Applications of Cardiovascular Magnetic Resonance
Current Pharmaceutical Design Antimicrobial Susceptibilities and Treatment Options for Pediatric Mycoplasma pneumoniae Infections - Does Macrolide Resistance Matter?
Current Pediatric Reviews COVID-19 Vaccination in Children: An Open Question
Current Pediatric Reviews Adverse Reactions Induced by Minocycline: A Review of Literature
Current Drug Safety Speculative Considerations about Some Cardiology Enigmas
Current Cardiology Reviews Perioperative Considerations in Rheumatoid Arthritis Patients
Current Rheumatology Reviews Do We Have Good Activity Indices in Systemic Sclerosis?
Current Rheumatology Reviews Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Gemcitabine-Related Atrial Fibrillation: A Case Report and Review of the Literature
Current Drug Safety Clinical Presentations and Diagnosis of Brucellosis
Recent Patents on Anti-Infective Drug Discovery Use of Medication in Coronary Imaging by CT
Current Medical Imaging Immune Therapy for Infectious Diseases at the Dawn of the 21st Century: the Past, Present and Future Role of Antibody Therapy, Therapeutic Vaccination and Biological Response Modifiers
Current Pharmaceutical Design The Current Role of Statin Therapy in the Treatment of Atrial Fibrillation
Cardiovascular & Hematological Agents in Medicinal Chemistry Inflammatory Arthritis and Heart Disease
Current Pharmaceutical Design MRI of Central Nervous System (CNS) Vasculitis
Current Medical Imaging Plausible Improvements for Selective Targeting of Dopamine Receptors in Therapy of Parkinson’s Disease
Mini-Reviews in Medicinal Chemistry